Extended Data Fig. 7: CSF amyloid and neurogranin. | Nature Aging

Extended Data Fig. 7: CSF amyloid and neurogranin.

From: ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Extended Data Fig. 7

a, Individual patient courses of CSF neurogranin levels. b, Both AADvac1 and placebo group showed decrease in neurogranin. (95% CI –48.913, 14.194; t-statistic –1.1355; df = 24; p = 0.26738; Cohen’s d –0.3154) Change from baseline (mean, 95% CI of mean shown). c, The decrease in CSF Aβ40 in AADvac1 and placebo patients is almost universal. d, Both treatment and placebo group showed decrease in Aβ40. (95% CI –2056.972, 280.813; t-statistic –1.5681; df = 24; p = 0.12996; Cohen’s d –0.3679) Change from baseline (mean, 95% CI of mean shown). e, Individual patient courses of CSF Aβ42 levels. f, Both treatment and placebo group showed decrease in Aβ42. (95% CI –47.001, 45.385; t-statistic –0.0361; df = 24; p = 0.97151, Cohen’s d –0.0228) Change from baseline (mean, 95% CI of mean shown). FAS, patients who provided baseline and end-of-study CSF samples, AADvac1 n = 20, placebo n = 7.

Source data

Back to article page